A novel bispecific antibody platform to direct complement activity for efficient lysis of target cells

A novel bispecific antibody platform to direct complement activity for efficient lysis of target cells

Abstract Harnessing complement-mediated cytotoxicity by therapeutic antibodies has been limited because of dependency on size and density of antigen, structural constraints resulting from orientation of antibody binding, and blockade of complement activation by inhibitors expressed on target cells....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jonathan W. Cruz, Ermelinda Damko, Bhavika Modi, Naxin Tu, Karoline Meagher, Vera Voronina, Hans Gartner, George Ehrlich, Ashique Rafique, Robert Babb, Priya Aneja, Terra B. Potocky, Amanda D’ Orvilliers, Alida Coppi, Sook Yen E, Haibo Qiu, Courtney M. Williams, Brandy L. Bennett, Gang Chen, Lynn Macdonald, William Olson, John C. Lin, Neil Stahl, Andrew J. Murphy, Christos A. Kyratsous, Brinda C. Prasad
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/a1c56187022f4047924380652a772499
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares